STAT

Experts challenge the science behind ban on psychiatrists discussing politicians’ mental health

A prohibition against psychiatrists discussing the mental health of public figures is “premised on dubious scientific assumptions,” researchers concluded.
Photos of Sen. Barry Goldwater during his 1964 campaign for president.

A prohibition against psychiatrists discussing the mental health of public figures — a rule that has become especially controversial, and sometimes flouted, since the inauguration of President Trump — is “premised on dubious scientific assumptions,” researchers concluded in an analysis scheduled for publication in a psychology journal.

The American Psychiatric Association (APA) defends its “” by arguing that an in-person psychiatric examination is the gold standard for diagnosing mental illness and psychological traits — given that there are no blood tests or brain scans for psychiatric disorders. In fact, however, numerous studies suggest that the interview-based exam can be misleading, psychologist Scott Lilienfeld of Emory University and colleagues argue in the

You’re reading a preview, subscribe to read more.

More from STAT

STAT2 min read
STAT+: Pharmalittle: We’re Reading About Lilly’s Zepbound For Sleep Apnea, The FDA Budget, And More
Eli Lilly reported positive results for Zepbound in obstructive sleep apnea, giving the medication a new edge in the highly competitive obesity market.
STAT2 min read
STAT+: Pharmalittle: We’re Reading About An Amgen Obesity Drug, A Senate Bill On Shortages, And More
Amgen will no longer develop an early-stage obesity pill, and will instead focus on a more advanced injectable candidate to compete with Wegovy and Zepbound.
STAT2 min read
STAT+: Pharmalittle: We’re Reading About A Senate Probe Into Novo Pricing, A New UTI Antibiotic, And More
The U.S. Senate health committee is investigating the prices Novo Nordisk charges for its blockbuster medications Ozempic and Wegovy.

Related Books & Audiobooks